OQROGet OQRO Pro
Insider trade

Enliven Therapeutics (ELVN)CFO sold ~$64K

Benjamin Hohl, CFO at Enliven Therapeutics, sold ~$64K of Enliven Therapeutics shares.

~$64K
Approx. value · 3,052 sh @ $20.86
23K
Holds after · shares reported
Traded
Jun 27, 2025
Filed
Jul 1, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Apr 28, 2025Insider · 1 personInsiders: 2 sales (~$61K)
  2. May 1, 2025Insider · 2 peopleInsiders: 2 sales (~$208K)
  3. May 2, 2025Insider · 2 peopleInsiders: 2 sales (~$93K)
  4. May 7, 2025Insider · 1 personInsiders: 3 sales (~$123K)
  5. May 19, 2025Insider · 2 peopleInsiders: 2 sales (~$164K)
  6. May 27, 2025InsiderCFO sold ~$53K of ELVN shares in the open market
  7. Jun 3, 2025Insider · 2 peopleInsiders: 2 sales (~$301K)
  8. Jun 9, 2025Insider · 1 personInsiders: 2 sales (~$136K)
  9. Jun 13, 2025InsiderCFO sold ~$68K of ELVN shares in the open market
  10. Jun 17, 2025Insider · 1 personInsiders: 2 sales (~$277K)
  11. Jun 20, 2025InsiderOfficer sold ~$267K of ELVN shares in the open market
  12. Jun 27, 2025 · this disclosureInsiderCFO sold ~$64K of ELVN shares in the open market

What came next

  1. Jun 27, 2025InsiderCFO sold ~$4.3K of ELVN shares in the open market
  2. Jul 7, 2025Insider · 1 personInsiders: 2 sales (~$132K)
  3. Jul 10, 2025InsiderCFO sold ~$23K of ELVN shares in the open market
  4. Jul 17, 2025Insider · 1 personInsiders: 3 sales (~$282K)
  5. Jul 21, 2025Insider · 1 personInsiders: 2 sales (~$279K)
  6. Jul 28, 2025Insider · 1 personInsiders: 2 sales (~$67K)
  7. Aug 7, 2025Insider · 1 personInsiders: 2 sales (~$122K)
  8. Aug 19, 2025InsiderOfficer sold ~$98K of ELVN shares in the open market
  9. Aug 20, 2025InsiderCEO sold ~$30K of ELVN shares in the open market
  10. Aug 21, 2025InsiderOfficer sold ~$150K of ELVN shares in the open market
  11. Aug 27, 2025InsiderCFO sold ~$67K of ELVN shares in the open market
  12. Sep 8, 2025InsiderOfficer sold ~$135K of ELVN shares in the open market
  13. Sep 17, 2025InsiderCEO sold ~$95K of ELVN shares in the open market
  14. Sep 19, 2025Insider · 2 peopleInsiders: 3 sales (~$156K)
  15. Sep 23, 2025Insider · 2 peopleInsiders: 2 sales (~$86K)
  16. Sep 26, 2025Insider · 2 peopleInsiders: 2 sales (~$155K)
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Enliven Therapeutics

For Enliven Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ELVN page.

Other recent filings by Benjamin Hohl, CHIEF FINANCIAL OFFICER

The full history of Benjamin Hohl, CHIEF FINANCIAL OFFICER is on the profile page.

How this filing works

Other disclosures at Enliven Therapeutics

Everything OQRO holds on this company is on its ELVN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data